Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 Moditope will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma rozpoznanego zaawansowanego raka piersi potrójnie ujemnego.
- •Pacjent ma rozpoznanego zaawansowanego raka płaskonabłonkowego głowy i szyi (jamie ustnej, gardła środkowego, gardła dolnego lub krtani), który nie nadaje się do leczenia operacyjnego z intencją wyleczenia.
- •Pacjent ma rozpoznanego zaawansowanego raka jajnika o wysokim stopniu złośliwości.
- •Pacjent ma rozpoznanego zaawansowanego raka nerki.
- •Pacjent ma raka płaskonabłonkowego głowy i szyi, który ma zostać poddany operacji z intencją wyleczenia.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 17, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
Brighton and Sussex University Hospital
Brighton, United Kingdom
Velindre Cancer Centre
Cardiff, United Kingdom
Edinburgh Cancer Centre (NHS Lothian)
Edinburgh, United Kingdom
Royal Surrey NHS Foundation
Guildford, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Mount Vernon
London, United Kingdom
University College London Hospital NHS Foundation Trust
London, United Kingdom
Christie NHS Foundation Trust
Manchester, United Kingdom
Nottingham University Hospitals Cancer Centre
Nottingham, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, United Kingdom
Sheffield Teaching Hospital NHS Foundation Trust
Sheffield, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Belfast City Hospital
Belfast, United Kingdom
Addenbrooke's Hospital, Cambridge University Hospitals
Cambridge, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, United Kingdom
Torbay and South Devon NHS Foundation Trust
Torquay, United Kingdom
Trial contact
Robert Miller
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.